Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 2, 2025
Purpose: Disclosure of an investor presentation (Exhibit 99.1) pursuant to Regulation FD. The presentation is intended for meetings with institutional investors and analysts.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to announce the availability of a corporate presentation; it does not contain audited financial statements or specific financial data points.
Material Changes
No material changes to financial performance or operations are detailed in the text of this filing. The document references an attached presentation (Exhibit 99.1) which may contain updates, but the content of that presentation is not included in the provided text.
Guidance, Outlook, and Risks
- Management Commentary: The Company states that the information in the investor presentation may be amended or updated at any time through future filings or other means.
- Availability: The presentation is available on the Company's website (www.aquestive.com) under the Events and Presentations section, though the Company reserves the right to discontinue availability.
- Legal Status: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the content of the attached "Corporate Presentation dated June 2025" (Exhibit 99.1) for specific financial data, as it is not present in the 8-K text.
- Confirm the current availability of the presentation on the Company's investor relations website.
- Note that the presentation is subject to amendment and does not constitute a formal filing under Section 18 of the Exchange Act.